An interventional study of Acoustic Radiation Force Impulse (ARFI) ultrasound in Plaque, Atherosclerotic, Carotid Artery Plaque and Carotid Stenosis, sponsored by University of North Carolina, Chapel Hill. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Plaque, Atherosclerotic with a site in United States — 1 open to participants now, 4 under way, 2 of them phase 3. Plaque, Atherosclerotic · United States.
Among the 19 studies in Plaque, Atherosclerotic with a site in United States, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2019, is one of 3 with no phase, and was the 16th registered.
105 studies on the registry are indexed under Plaque, Atherosclerotic; 27 are open to participants now.
Browse Plaque, Atherosclerotic studies →1 of the 19 studies in Plaque, Atherosclerotic with a site in United States is open now. Recruiting first, the newest first:
Ischemia Care LLC · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 16 Plaque, Atherosclerotic studies recruiting now, 7 (44%) set no upper age limit and 4 (25%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 1 · Phase 3 6 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is below the median of 160 across 51 interventional studies indexed under Plaque, Atherosclerotic.
Median enrollment 259 across the 14 interventional studies, 230 across the 5 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
University of North Carolina, Chapel Hill is the lead sponsor of 1,373 studies on the registry; 134 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 140 (86%) have results posted.
University of North Carolina, Chapel Hill has 1 study filed under Plaque, Atherosclerotic — fewer than ten, so there is no comparison to draw.
2 of the studies in Plaque, Atherosclerotic with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06305559Phase 3NewAmsterdam PharmaA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | 2027-11 |
| NCT04063709University of North Carolina, Chapel HillTranscutaneous ARFI Ultrasound for Differentiating Carotid Plaque With High Stroke Risk | 2027-08 |
Add all 2 to your calendar (.ics) → With an account.
Among the 19 studies in Plaque, Atherosclerotic with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Stroke is a leading cause of death and disability in the United States and around the world. The goal of this work is to develop and test a noninvasive ultrasound-based imaging technology to better identify patients at high risk of stroke so that appropriate and timely intervention may be administered to prevent it.
Although stroke remains a leading cause of death in the United States, incidence and mortality rates have declined over the past two decades in association with advanced pharmaceutical therapies and revascularization, primarily by carotid endarterectomy (CEA). While CEA's efficacy for preventing stroke in patients with severe (≥70%) carotid artery stenosis and neurological symptoms is well documented, the surgical intervention's usefulness decreases as stroke risk falls in patients with less severe stenosis and patients without symptoms. It is estimated that as many as 13 out of 14 symptomatic patients with 50-69% stenosis and 21 out of 22 asymptomatic patients with 70-99% stenosis undergo CEA surgery unnecessarily. These data demonstrate the inadequacy of degree of stenosis as the primary indication of stroke risk and underscore the urgent yet unmet need for improved biomarkers that differentiate patients at low risk of embolic stroke from those in need of CEA to prevent it.
This urgent need for improving CEA indication could be met by assessing the structure and composition of carotid plaques. Plaques composed of thin or ruptured fibrous caps (TRFC), large lipid rich necrotic cores (LRNC), and intraplaque hemorrhage (IPH) are associated with thrombosis in morphological studies from autopsy. Further, plaque hemorrhage and increased intraplaque vessel formation in CEA specimens are independently related to future cardio- and cerebrovascular events or interventions. Finally, previous stroke or transient ischemic attack (TIA) is associated with TRFC and IPH - while increased risk of future stroke or TIA is conferred by TRFC, LRNC, and IPH - in human carotid plaques as determined by in vivo magnetic resonance imaging (MRI).
The goal of this work is to develop a low-cost, noninvasive imaging method that reliably delineates carotid plaque structure and composition and is suitable for widespread diagnostic application. Previous research has demonstrated that Acoustic Radiation Force Impulse (ARFI) ultrasound delineates LRNC/IPH, collagen/calcium deposits, and TRFC in human carotid plaque, in vivo, with TRFC thickness measurement as low as 0.49 mm - the mean thickness associated with rupture. This project will exploit ARFI Variance of Acceleration (VoA) imaging, higher center frequencies, and harmonic imaging to newly enable separate discrimination of TRFC, LRNC, and IPH and accurate feature size measurement. The investigators will determine the association between advanced ARFI's plaque characterization and recent history of ipsilateral stroke or TIA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 50-69% stenotic carotid plaque with associated neurological symptoms. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging will be performed on the carotid plaque.
Diagnostic Test: Acoustic Radiation Force Impulse (ARFI) ultrasound
Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque with associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
Diagnostic Test: Acoustic Radiation Force Impulse (ARFI) ultrasound
Patients 18 years of age or older who have been selected by their treating physician to be in need of carotid revascularization by CEA, with 70-99% stenotic carotid plaque without associated neurological symptoms. ARFI ultrasound imaging will be performed on the carotid plaque.
Diagnostic Test: Acoustic Radiation Force Impulse (ARFI) ultrasound
Patients 18 years of age or older who have been diagnosed with 50-69% carotid artery stenosis without clinical indication for CEA.
Diagnostic Test: Acoustic Radiation Force Impulse (ARFI) ultrasound
ARFI imaging is an ultrasound-based, noninvasive imaging method and will be used in accordance with approved labeling.
Acoustic Radiation Force Impulse (ARFI) imaging
Ability of ARFI imaging to detect carotid plaque features and measure their size
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for thin or ruptured fibrous caps (TRFC) at 8 MHz fundamental
Area Under the Curve (AUC) for the ability of ARFI Variance of Acceleration (VoA) obtained at 8 MHz fundamental frequency to detect thin or ruptured fibrous cap
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for TRFC at 8 MHz fundamental
AUC for the ability of ARFI PD obtained at 8 MHz fundamental frequency to detect thin or ruptured fibrous cap
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for TRFC at 12 MHz fundamental
AUC for the ability of ARFI VoA obtained at 12 MHz fundamental frequency to detect thin or ruptured fibrous cap
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for TRFC at 12 MHz fundamental
AUC for the ability of ARFI PD obtained at 12 MHz fundamental frequency to detect thin or ruptured fibrous cap
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for TRFC at 12 MHz harmonic
AUC for the ability of ARFI VoA obtained at 12 MHz harmonic frequency to detect thin or ruptured fibrous cap
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for TRFC at 12 MHz harmonic
AUC for the ability of ARFI PD obtained at 12 MHz harmonic frequency to detect thin or ruptured fibrous cap
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for LRNC at 8 MHz fundamental
AUC for the ability of ARFI VoA obtained at 8 MHz fundamental frequency to detect lipid rich necrotic core (LRNC)
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for LRNC at 8 MHz fundamental
AUC for the ability of ARFI PD obtained at 8 MHz fundamental frequency to detect lipid rich necrotic core
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for LRNC at 12 MHz fundamental
AUC for the ability of ARFI VoA obtained at 12 MHz fundamental frequency to detect lipid rich necrotic core
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for LRNC at 12 MHz fundamental
AUC for the ability of ARFI PD obtained at 12 MHz fundamental frequency to detect lipid rich necrotic core
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for LRNC at 12 MHz harmonic
AUC for the ability of ARFI VoA obtained at 12 MHz harmonic frequency to detect lipid rich necrotic core
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for LRNC at 12 MHz harmonic
AUC for the ability of ARFI PD obtained at 12 MHz harmonic frequency to detect lipid rich necrotic core
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for IPH at 8 MHz fundamental
AUC for the ability of ARFI VoA obtained at 8 MHz fundamental frequency to detect intraplaque hemorrhage
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for IPH at 8 MHz fundamental
AUC for the ability of ARFI PD obtained at 8 MHz fundamental frequency to detect intraplaque hemorrhage
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for IPH at 12 MHz fundamental
AUC for the ability of ARFI VoA obtained at 12 MHz fundamental frequency to detect intraplaque hemorrhage
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for IPH at 12 MHz fundamental
AUC for the ability of ARFI PD obtained at 12 MHz fundamental frequency to detect intraplaque hemorrhage
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA AUC for IPH at 12 MHz harmonic
AUC for the ability of ARFI VoA obtained at 12 MHz harmonic frequency to detect intraplaque hemorrhage
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD AUC for IPH at 12 MHz harmonic
AUC for the ability of ARFI PD obtained at 12 MHz harmonic frequency to detect intraplaque hemorrhage
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for TRFC thickness at 8 MHz fundamental
Bland Altman-derived bias in VoA-based TRFC thickness measurement 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for TRFC thickness at 8 MHz fundamental
Bland Altman-derived bias in PD-based TRFC thickness measurement 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for TRFC thickness at 12 MHz fundamental
Bland Altman-derived bias in VoA-based TRFC thickness measurement at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for TRFC thickness at 12 MHz fundamental
Bland Altman-derived bias in PD-based TRFC thickness measurement at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for TRFC thickness at 12 MHz harmonic
Bland Altman-derived bias in VoA-based TRFC thickness measurement at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for TRFC thickness at 12 MHz harmonic
Bland Altman-derived bias in PD-based TRFC thickness measurement at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for LRNC size at 8 MHz fundamental
Bland Altman-derived bias in VoA-based LRNC size measurement at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for LRNC size at 8 MHz fundamental
Bland Altman-derived bias in PD-based LRNC size measurement at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for LRNC size at 12 MHz fundamental
Bland Altman-derived bias in VoA-based LRNC size measurement at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for LRNC size at 12 MHz fundamental
Bland Altman-derived bias in PD-based LRNC size measurement at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for LRNC size at 12 MHz harmonic
Bland Altman-derived bias in VoA-based LRNC size measurement at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for LRNC size at 12 MHz harmonic
Bland Altman-derived bias in PD-based LRNC size measurement at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for IPH size at 8 MHz fundamental
Bland Altman-derived bias in VoA-based IPH size measurement at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for IPH size at 8 MHz fundamental
Bland Altman-derived bias in PD-based IPH size measurement at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for IPH size at 12 MHz fundamental
Bland Altman-derived bias in VoA-based IPH size measurement at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for IPH size at 12 MHz fundamental
Bland Altman-derived bias in PD-based IPH size measurement at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA bias for IPH size at 12 MHz harmonic
Bland Altman-derived bias in VoA-based IPH size measurement at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD bias for IPH size at 12 MHz harmonic
Bland Altman-derived bias in PD-based IPH size measurement at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of TRFC detection at 8 MHz fundamental
prevalence of reader-detected TRFC from VoA at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of TRFC detection at 8 MHz fundamental
prevalence of reader-detected TRFC from PD at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of TRFC detection at 12 MHz fundamental
prevalence of reader-detected TRFC from VoA at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of TRFC detection at 12 MHz fundamental
prevalence of reader-detected TRFC from PD at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of TRFC detection at 12 MHz harmonic
prevalence of reader-detected TRFC from VoA at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of TRFC detection at 12 MHz harmonic
prevalence of reader-detected TRFC from PD at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of LRNC detection at 8 MHz fundamental
prevalence of reader-detected LRNC from VoA at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of LRNC detection at 8 MHz fundamental
prevalence of reader-detected LRNC from PD at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of LRNC detection at 12 MHz fundamental
prevalence of reader-detected LRNC from VoA at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of LRNC detection at 12 MHz fundamental
prevalence of reader-detected LRNC from PD at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of LRNC detection at 12 MHz harmonic
prevalence of reader-detected LRNC from VoA at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of LRNC detection at 12 MHz harmonic
prevalence of reader-detected LRNC from PD at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of IPH detection at 8 MHz fundamental
prevalence of reader-detected IPH from VoA at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of IPH detection at 8 MHz fundamental
prevalence of reader-detected IPH from PD at 8 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of IPH detection at 12 MHz fundamental
prevalence of reader-detected IPH from VoA at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of IPH detection at 12 MHz fundamental
prevalence of reader-detected IPH from PD at 12 MHz fundamental frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
VoA prevalence of IPH detection at 12 MHz harmonic
prevalence of reader-detected IPH from VoA at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PD prevalence of IPH detection at 12 MHz harmonic
prevalence of reader-detected IPH from PD at 12 MHz harmonic frequency
Time frame: Upon completion of the development of all novel ARFI data processing algorithms, their application to all acquired ARFI data, and the interpretation of the results for all participants, an average of two years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Deidentified individual data pertaining to the study protocol and the statistical analysis plan that support the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Deidentified individual data pertaining to the study protocol and the statistical analysis plan that support the results will be shared beginning 9 to 36 months following publication.
Access criteria: An investigator who proposes to use the data must have approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and execute a data use/sharing agreement with UNC.
Started Jul 2019 (actual). Primary completion is estimated for Aug 2027, 97 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →